Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS): 11 pipeline candidates · ~51 mo cash runway · 52 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
51.2 months
D/E 0.67 · 0% dilution
N/A
11 candidates
N/A
0 buys · 32 sells (180d)
A transparent, data-derived signal for Tarsus Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.7B
Cash
$104.2M
Quarterly Burn
$24.7M
Runway
51.2 mo
Revenue
$162.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| Lotilaner ophthalmic solution, 0.25% | Phase 4 |
| TP-03 | Phase 4 |
| TP-03 (XDEMVY) for MGD (Ersa and Rhea trials) | Phase 4 |
| TP-03 Vehicle | Phase 4 |
| TP-04 | Phase 4 |
| TP-04 (novel ophthalmic gel formulation of lotilaner) | Phase 4 |
| TP-05 | Phase 4 |
| TP-05 (investigational oral tablet formulation of lotilaner) | Phase 4 |
| TP-05 (novel investigational oral formulation of lotilaner) | Phase 4 |
| Vehicle control | Phase 4 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
252
Total value held
$3.13B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,481,926 | $314.4M |
| deep track capital, lp | 3,600,000 | $252.5M |
| blackrock, inc. | 3,552,612 | $249.2M |
| vanguard capital management llc | 3,521,082 | $247.0M |
| rtw investments, lp | 3,346,025 | $234.7M |
| morgan stanley | 1,944,272 | $136.4M |
| jennison associates llc | 1,712,124 | $120.1M |
| bank of america corp /de/ | 1,194,377 | $83.8M |
| tang capital management llc | 1,188,624 | $83.4M |
| geode capital management, llc | 1,121,091 | $78.7M |
Showing top 10 of 252 institutional holders of Tarsus Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tarsus Pharmaceuticals, Inc.'s pipeline?
Tarsus Pharmaceuticals, Inc. (TARS) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tarsus Pharmaceuticals, Inc.'s lead drug candidate?
Tarsus Pharmaceuticals, Inc.'s most advanced tracked candidate is Lotilaner ophthalmic solution, 0.25% (Phase 4) for Demodex Blepharitis.
What is Tarsus Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tarsus Pharmaceuticals, Inc. has approximately 51.2 months of cash runway.
What is Tarsus Pharmaceuticals, Inc.'s market capitalization?
Tarsus Pharmaceuticals, Inc.'s market capitalization is approximately $2.7B.
Who is the CEO of Tarsus Pharmaceuticals, Inc.?
Dr. Bobak R. Azamian M.D. is the chief executive officer of Tarsus Pharmaceuticals, Inc. (TARS).
Get the full picture on Tarsus Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.